Mental Health Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Boston Scientific Corp.
Clinical trial to assess precision spinal cord stimulator for treatment of migraine headaches
December 17th, 2005
Boston Scientific Corp. (BSX) announced that it has received approval from the U.S. Food and Drug Administration (FDA) to begin a prospective, randomized, double-blind pivotal trial to evaluate the safety and efficacy of occipital nerve stimulation as a treatment for refractory migraine headache. The study, known as PRISM (PRecision Implantable Stimulator for Migraine), will use Boston Scientific's Precision neurostimulator and involve approximately 150 patients at up to 15 sites in the U.S. The Precision device is the smallest rechargeable neurostimulator on the market today and is already approved by the FDA for spinal cord stimulation to treat...
Source: Mental Health Law Weekly (2005-12-17)
|
